Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Department of Gastroenterology, The second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Int Immunopharmacol. 2024 Sep 30;139:112635. doi: 10.1016/j.intimp.2024.112635. Epub 2024 Jul 12.
To investigate the clinical efficacy and adverse reactions of gemcitabine/nab-paclitaxel (AG regimen) combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer (PC).
Data of 52 patients with advanced PC who were treated in the Affiliated Hospital of Xuzhou Medical University (Xuzhou, China) between August 2019 and March 2023 were retrospectively analyzed. According to the treatment regimen, patients were divided into two groups, including 27 patients in the chemotherapy group (AG regimen) and 25 patients in the combined treatment group (AG regimen combined with anlotinib and PD-1 inhibitors). Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse reactions were compared between the two groups. The survival curves of the two groups were drawn using the Kaplan-Meier method, and the differences in PFS and OS between the two groups were compared by the log-rank test. Univariate and multivariate Cox regression analyses were performed to identify independent risk factors influencing prognosis.
The median OS and PFS in the combined treatment group were significantly longer than those in the chemotherapy group (OS, 12.8 vs. 7.9 months, P = 0.005; PFS, 5.6 vs. 4.4 months, P = 0.003). There was no significant difference in ORR between the two groups (32.0 % vs. 25.9 %, P = 0.629), and DCR in the combined treatment group was significantly better than that in the chemotherapy group (84.0 % vs. 59.3 %, P = 0.049). Grade 1-2 adverse reactions were predominant in both groups, and no adverse reaction-related deaths occurred.
Compared with chemotherapy alone, AG regimen combined with anlotinib and PD-1 inhibitors exhibited to have a higher efficacy for the first-line treatment of advanced PC, and the adverse reactions were also controllable.
探讨吉西他滨/白蛋白紫杉醇（AG 方案）联合安罗替尼和 PD-1 抑制剂作为晚期胰腺癌（PC）一线治疗的临床疗效和不良反应。
回顾性分析 2019 年 8 月至 2023 年 3 月在徐州医科大学附属医院（徐州，中国）接受治疗的 52 例晚期 PC 患者的数据。根据治疗方案，患者分为两组，化疗组（AG 方案）27 例，联合治疗组（AG 方案联合安罗替尼和 PD-1 抑制剂）25 例。比较两组患者的总生存期（OS）、无进展生存期（PFS）、客观缓解率（ORR）、疾病控制率（DCR）和不良反应。采用 Kaplan-Meier 法绘制两组患者的生存曲线，采用对数秩检验比较两组患者的 PFS 和 OS 差异。采用单因素和多因素 Cox 回归分析识别影响预后的独立危险因素。
联合治疗组的中位 OS 和 PFS 明显长于化疗组（OS：12.8 个月比 7.9 个月，P=0.005；PFS：5.6 个月比 4.4 个月，P=0.003）。两组患者的 ORR 无显著差异（32.0%比 25.9%，P=0.629），联合治疗组的 DCR 明显优于化疗组（84.0%比 59.3%，P=0.049）。两组患者均以 1-2 级不良反应为主，无不良反应相关死亡事件发生。
与单纯化疗相比，AG 方案联合安罗替尼和 PD-1 抑制剂治疗晚期 PC 的疗效更高，不良反应也可控制。
